City Holding Co. raised its stake in GlaxoSmithKline PLC (NYSE:GSK) by 12.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 45,342 shares of the pharmaceutical company’s stock after buying an additional 5,094 shares during the period. City Holding Co.’s holdings in GlaxoSmithKline PLC were worth $1,955,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Norges Bank acquired a new position in GlaxoSmithKline PLC during the fourth quarter valued at approximately $19,206,000. Dodge & Cox acquired a new position in GlaxoSmithKline PLC during the fourth quarter valued at approximately $1,416,000. Perigon Wealth Management LLC boosted its position in GlaxoSmithKline PLC by 3.3% in the fourth quarter. Perigon Wealth Management LLC now owns 44,720 shares of the pharmaceutical company’s stock valued at $1,904,000 after buying an additional 1,427 shares during the period. M Holdings Securities Inc. boosted its position in GlaxoSmithKline PLC by 13.3% in the fourth quarter. M Holdings Securities Inc. now owns 15,042 shares of the pharmaceutical company’s stock valued at $579,000 after buying an additional 1,764 shares during the period. Finally, Searle & CO. acquired a new position in GlaxoSmithKline PLC during the fourth quarter valued at approximately $586,000. Institutional investors and hedge funds own 8.96% of the company’s stock.

GlaxoSmithKline PLC (GSK) opened at 42.26 on Tuesday. The stock’s 50 day moving average price is $43.56 and its 200 day moving average price is $41.27. The company has a market capitalization of $103.24 billion, a price-to-earnings ratio of 47.59 and a beta of 1.05. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $45.58.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 EPS for the quarter, hitting analysts’ consensus estimates of $0.62. The firm had revenue of $9.23 billion during the quarter, compared to analysts’ expectations of $9.09 billion. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. On average, equities research analysts anticipate that GlaxoSmithKline PLC will post $2.86 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, July 13th. Shareholders of record on Friday, May 12th were paid a dividend of $0.483 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date was Wednesday, May 10th. This represents a $1.93 dividend on an annualized basis and a yield of 4.57%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 233.74%.

ILLEGAL ACTIVITY WARNING: “City Holding Co. Has $1.96 Million Position in GlaxoSmithKline PLC (GSK)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/07/18/city-holding-co-has-1-96-million-position-in-glaxosmithkline-plc-gsk.html.

Several research analysts recently commented on GSK shares. Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, March 29th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, April 5th. BNP Paribas upgraded GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and cut their price target for the stock from $45.58 to $37.20 in a research note on Wednesday, April 5th. Exane BNP Paribas upgraded GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a research note on Wednesday, April 5th. Finally, TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and a consensus target price of $45.25.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.